The randomised, open label, phase III COMPARZ (Comparing the Efficacy, Safety, and Tolerability of Pazopanib vs. Sunitinib) trial was a head-to-head comparison of the efficacy, safety and tolerability of pazopanib versus sunitinib in treatment-naive patients with clear cell metastatic renal cell carcinoma with measurable disease. Pazopanib demonstrated non-inferiority to sunitinib and shows a more favourable safety profile and improved patient reported quality of life domains. Read more here.
Study mentioned: Motzer RJ, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013 Aug 22;369(8):722-31. PMID: 23964934
No comments:
Post a Comment